Dr. Reddy’s Laboratories Ltd
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.4% | +3.9% | +7.2% | +12.2% | +3.2% | +2.5% | +5.4% | +4.3% | +3.9% | +0.9% | +1.3% | |
| – | +9.5% | +4.0% | +8.5% | -7.8% | +2.0% | -1.1% | +7.9% | +3.6% | +6.5% | -0.5% | +1.1% | |
| – | -45.2% | -3.2% | -30.9% | +130.6% | +8.5% | +19.2% | -38.6% | +10.0% | +88.3% | -19.3% | -25.6% | |
| – | +6.8% | +12.6% | +16.1% | -33.3% | -6.2% | -2.1% | +15.2% | +4.7% | +18.3% | +4.2% | -5.4% | |
| – | +7.1% | -0.8% | -14.9% | +26.8% | +8.4% | -1.5% | +5.1% | +4.7% | +2.8% | -20.2% | +25.4% | |
| – | +7.4% | +4.5% | +7.9% | +5.1% | -0.6% | -0.8% | +6.4% | +0.3% | +4.2% | -5.1% | +7.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.5% | -0.8% | -0.2% | +177.5% | +0.7% | -0.4% | +1.4% | +2.7% | +0.9% | +1.8% | +1.8% | |
| – | -0.4% | +0.1% | +0.5% | +148.1% | +0.9% | +4.2% | -1.2% | +5.6% | +1.4% | +0.6% | +0.6% | |
| – | +11.8% | +1.9% | +12.8% | +29.8% | +1.8% | -2.3% | +6.4% | +8.5% | +4.0% | +4.2% | -3.3% | |
| – | +11.2% | +2.6% | +10.0% | +22.4% | +2.1% | -1.2% | +9.4% | +5.8% | +4.9% | +3.8% | -4.2% | |
| – | +90.6% | +2.4% | +74.2% | +68.4% | +5.7% | -10.6% | +11.9% | +7.7% | +19.7% | +13.8% | -5.9% | |
| – | +2.1% | -30.7% | +58.3% | +4.9% | +0.7% | -44.3% | +86.8% | +7.5% | +1.4% | -19.7% | +14.5% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | – | – | – | – | – | |
| – | +5.8% | +4.7% | +5.0% | +3.6% | +4.1% | +4.9% | +5.0% | +2.4% | +3.9% | -0.7% | +3.7% | |
| – | +5.8% | +5.2% | +5.3% | +2.1% | +5.0% | +5.5% | +4.5% | +2.3% | +3.6% | -1.4% | +3.3% | |
| – | -80.0% | +400.0% | 0.0% | +0.0% | +0.0% | +0.0% | -0.2% | +0.0% | +0.0% | +0.2% | -0.3% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.